Robert G Bristow Selected Research

Radiation-Sensitizing Agents

7/2021	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.
1/2016	In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer.
9/2015	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.
12/2014	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
11/2014	Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells.
6/2010	Gold nanoparticles as radiation sensitizers in cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert G Bristow Research Topics

Disease

90	Neoplasms (Cancer) 01/2022 - 05/2003
80	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 12/2004
36	Hypoxia (Hypoxemia) 01/2022 - 10/2004
14	Neoplasm Metastasis (Metastasis) 10/2021 - 10/2010
9	Breast Neoplasms (Breast Cancer) 04/2020 - 01/2010
7	Urinary Bladder Neoplasms (Bladder Cancer) 02/2019 - 07/2007
5	Genomic Instability 11/2021 - 12/2014
5	Carcinoma (Carcinomatosis) 09/2020 - 09/2005
4	Adenocarcinoma 01/2019 - 05/2012
3	Carcinogenesis 01/2020 - 12/2005
3	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2012 - 09/2002
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 10/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 11/2012
2	Triple Negative Breast Neoplasms 01/2017 - 01/2016
2	Lung Neoplasms (Lung Cancer) 01/2016 - 06/2012
2	Chromosomal Instability (Chromosome Stability) 01/2014 - 01/2012
2	Tics (Tic) 01/2012 - 01/2010
1	Stress Fractures (Stress Fracture) 01/2022
1	Disease Progression 09/2020
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2019
1	Circulating Neoplastic Cells 01/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2018

Drug/Important Bio-Agent (IBA)

29	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2004
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2003
17	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2007
12	AndrogensIBA 01/2021 - 09/2005
10	Oxygen (Dioxygen)IBA 01/2020 - 01/2006
8	Messenger RNA (mRNA)IBA 10/2021 - 10/2004
8	RNA (Ribonucleic Acid)IBA 10/2021 - 08/2005
8	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 09/2005
8	Biological ProductsIBA 01/2016 - 03/2008
7	ChromatinIBA 12/2021 - 12/2005
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 08/2008
7	Pharmaceutical PreparationsIBA 01/2018 - 03/2013
7	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 09/2013 - 08/2005
6	NucleotidesIBA 11/2021 - 07/2015
6	Radiation-Sensitizing AgentsIBA 07/2021 - 06/2010
6	Cisplatin (Platino)FDA LinkGeneric 02/2019 - 07/2007
5	Hormones (Hormone)IBA 01/2022 - 02/2011
4	olaparibIBA 04/2020 - 09/2015
4	GoldIBA 01/2017 - 06/2010
4	Small Interfering RNA (siRNA)IBA 01/2016 - 01/2008
3	AntigensIBA 01/2022 - 10/2010
3	MicroRNAs (MicroRNA)IBA 01/2020 - 12/2013
3	Prostaglandins AIBA 01/2018 - 08/2012
3	Long Noncoding RNAIBA 11/2017 - 10/2016
3	Metformin (Glucophage)FDA LinkGeneric 01/2016 - 09/2010
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 08/2014 - 12/2004
3	AMP-Activated Protein KinasesIBA 03/2012 - 09/2010
2	Radioisotopes (Radionuclides)IBA 01/2021 - 05/2013
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 09/2017
2	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 01/2019
2	Complement System Proteins (Complement)IBA 01/2018 - 12/2014
2	Phenobarbital (Luminal)FDA Link 01/2017 - 05/2012
2	Kallikreins (Kallikrein)IBA 01/2017 - 01/2017
2	PlatinumIBA 01/2016 - 06/2012
2	Phosphotransferases (Kinase)IBA 12/2013 - 06/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 12/2013 - 10/2010
2	Imatinib Mesylate (Gleevec)FDA Link 03/2013 - 01/2009
2	Green Fluorescent ProteinsIBA 10/2011 - 01/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2007 - 08/2005
1	LigandsIBA 01/2022
1	Vitamin K 3 (Menadione)FDA Link 07/2021
1	Gemcitabine FDA Link 07/2021
1	lissamine rhodamine B (sulforhodamine B)IBA 07/2021
1	CXC ChemokinesIBA 09/2020
1	2- (3- (1- carboxy- 5- ((6- fluoropyridine- 3- carbonyl)amino)pentyl)ureido)pentanedioic acidIBA 01/2020
1	ProdrugsIBA 01/2019
1	TH 302IBA 01/2019
1	Circulating Tumor DNAIBA 01/2019
1	Circular RNAIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	ProteomeIBA 01/2019
1	Niacinamide (Nicotinamide)FDA LinkGeneric 05/2018
1	carbogenIBA 05/2018
1	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2018
1	Investigational DrugsIBA 01/2018
1	serratiopeptidaseIBA 10/2017
1	Serine Proteases (Serine Protease)IBA 01/2017
1	Tissue Kallikreins (Tissue Kallikrein)IBA 01/2017
1	N 563IBA 01/2017
1	Plasma KallikreinIBA 01/2017
1	bicalutamide (Casodex)FDA LinkGeneric 08/2016
1	Beclin-1IBA 01/2016

Therapy/Procedure

60	Radiotherapy 01/2022 - 07/2003
48	Therapeutics 01/2022 - 05/2003
11	Drug Therapy (Chemotherapy) 10/2017 - 07/2007
10	Image-Guided Radiotherapy 01/2019 - 09/2008
8	Castration 01/2022 - 02/2015
7	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 07/2008
4	Neoadjuvant Therapy 02/2019 - 07/2007
3	Immunotherapy 01/2021 - 01/2018
3	Chemoradiotherapy 02/2019 - 08/2009
3	Cystectomy 02/2019 - 09/2010
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2017 - 09/2009
2	Laser Therapy (Surgery, Laser) 01/2016 - 01/2006
2	Precision Medicine 02/2015 - 09/2010
2	Electrodes (Electrode) 09/2009 - 06/2007
1	Cytoreduction Surgical Procedures 01/2021
1	Transurethral Resection of Bladder 07/2017